Literature DB >> 12067217

Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms.

M Tobi1, J Hatfield, V Adsay, K Galagan, R Kozarek, M Inagaki, S Kasai, Y Tokusashi, T Obara, R H Hruban, J Lough, A N Barkun, M Jabbari, R Sheikh, B Ruebner, M J Lawson, E Ben-Josef, S Fligiel.   

Abstract

BACKGROUND: Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis.
METHODS: We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques.
RESULTS: 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p < 0.001) and 53% of adenomas (p < 0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027).
CONCLUSION: Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12067217     DOI: 10.1385/IJGC:29:3:141

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  27 in total

1.  Immunohistochemical demonstration of pancreatic secretory proteins in human paneth cells.

Authors:  M Bohe; C Lindström; K Ohlsson
Journal:  Scand J Gastroenterol Suppl       Date:  1986

2.  Management of intraductal papillary mucinous tumours of the pancreas.

Authors:  F Navarro; J Michel; P Bauret; J Ramos; P Blanc; J M Fabre; B Millat; B Desrousseaux; J Domergue
Journal:  Eur J Surg       Date:  1999-01

3.  Cell lineage markers in premalignant and malignant colonic mucosa.

Authors:  S B Ho; S H Itzkowitz; A M Friera; S H Jiang; Y S Kim
Journal:  Gastroenterology       Date:  1989-08       Impact factor: 22.682

4.  Mucosal origin and shedding of an early colonic tumor marker defined by Adnab-9 monoclonal antibody.

Authors:  M Tobi; Y Elitsur; M P Moyer; A Halline; M Deutsch; L Nochomovitz; G D Luk
Journal:  Scand J Gastroenterol       Date:  1993-12       Impact factor: 2.423

5.  Characteristics and treatment of mucin-producing tumor of the pancreas.

Authors:  W Kimura; M Makuuchi; A Kuroda
Journal:  Hepatogastroenterology       Date:  1998 Nov-Dec

6.  Intraductal papillary mucinous neoplasms of the pancreas associated with so-called "mucinous ductal ectasia". Histochemical and immunohistochemical analysis of 29 cases.

Authors:  E Nagai; T Ueki; K Chijiiwa; M Tanaka; M Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  1995-05       Impact factor: 6.394

Review 7.  Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms.

Authors:  Y M Shyr; C H Su; S H Tsay; W Y Lui
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

8.  Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.

Authors:  F Sessa; E Solcia; C Capella; M Bonato; A Scarpa; G Zamboni; N S Pellegata; G N Ranzani; F Rickaert; G Klöppel
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Cellular distribution of a colonic adenoma-associated antigen as defined by monoclonal antibody Adnab-9.

Authors:  M Tobi; B J Maliakkal; M A Alousi; V Voruganti; M Shafiuddin; S Yang; M S Gesell; T An; J S Hatfield; S Fligiel
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

10.  The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia.

Authors:  M MacPhee; K P Chepenik; R A Liddell; K K Nelson; L D Siracusa; A M Buchberg
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

View more
  4 in total

1.  Octreotide uptake in intracranial metastasis of pancreatic ductal adenocarcinoma origin in a patient with a prolonged clinical course.

Authors:  Rama Marepaily; Dan Micheals; Andrew Sloan; James Hatfield; Volkan Adsay; Richard Joyrich; Nadeem Ullah; Martin Tobi
Journal:  Dig Dis Sci       Date:  2008-11-05       Impact factor: 3.199

2.  Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma.

Authors:  Martin Tobi; Mijin Kim; Douglas H Weinstein; Mary Ann Rambus; James Hatfield; N Volkan Adsay; Edi Levi; Douglas Evans; Michael J Lawson; Suzanne Fligiel
Journal:  Dig Dis Sci       Date:  2012-09-22       Impact factor: 3.199

3.  An anti-adenoma antibody, Adnab-9, may reflect the risk for neoplastic progression in familial hamartomatous polyposis syndromes.

Authors:  Martin Tobi; Michael Kam; Nadeem Ullah; Kashif Qureshi; Violeta Yordanova; James Hatfield; Suzanne E G Fligiel; Paula Sochacki; Thomas McGarrity; Carolyn Cole; Michael Lawson; Russell Jacoby
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

4.  The use of early and midpoint adenoma-carcinoma sequence biomarkers in prediction of neoplastic progression in patients with a history of colorectal neoplasia.

Authors:  Hassan Albataineh; Violeta Yordanova; Jessica Bowman; Weili Zhou; James Hatfield; Michael J Lawson; Paula Sochacki; Martin Tobi
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.